We are currently looking for interventional study ideas that have potential for future implementation with the ARLG. Of particular interest are early study ideas that fill the most critical knowledge gaps and have the largest impact on clinical practice. Some areas of interest are listed to the right, but all ideas are welcome.
Impact on Clinical Outcomes
Prevention of Resistance
Submit Your Idea
Researchers with ideas for consideration can submit a short synopsis. Please be sure to include:
- Primary outcome measure
- Study design
Synopses should be a maximum of a half page (250 words) in length. The committee is not seeking fully developed proposals at this point.
The deadline for submissions is March 31. At that time, the committee will review all submissions and invite researchers to submit full synopses.
Deadline: March 31, 2020
About the Gram-Negative Committee
The Gram-Negative Committee’s goal is to expand the knowledge of challenging resistant gram-negative infections to improve patient outcomes. We do this by identifying novel antimicrobial agents, finding innovative treatment strategies, uncovering new ways to optimize antibiotic administration, and creating strategies to prevent resistance. An integral part of ARLG, we advance the study of gram-negative infections by conceiving and designing clinical trials, reviewing and prioritizing study protocols, and mentoring ARLG junior investigators.
Gram-Negative Committee Chair
Yohei Doi, MD, PhD
Division of Infectious Diseases
University of Pittsburgh School of Medicine